Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Evolus, Inc.    EOLS

EVOLUS, INC.

(EOLS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Evolus : ROSEN, A TOP RANKED LAW FIRM, Reminds Evolus, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – EOLS

10/29/2020 | 03:36pm EST

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Evolus, Inc. (NASDAQ: EOLS) between February 1, 2019 and July 6, 2020, inclusive (the “Class Period”), of the important December 15, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Evolus investors under the federal securities laws.

To join the Evolus class action, go to http://www.rosenlegal.com/cases-register-1954.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the real source of botulinum toxin bacterial strain as well as the manufacturing processes used to develop Jeuveau™ originated with and were misappropriated from Medytox; (2) sufficient evidentiary support existed for the allegations that Evolus misappropriated certain trade secrets relating to the botulin toxin strain and the manufacturing processes for the development of Jeuveau™; (3) as a result, Evolus faced a real threat of regulatory and/or court action, prohibiting the import, marketing, and sale of Jeuveau™; (4) which in turn seriously threatened Evolus’ ability to commercialize Jeuveau™ in the United States and generate revenue; and (5) any revenues generated from the sale of Jeuveau™ were based on Evolus’ unlawful activities, including the misappropriation of trade secrets and secret manufacturing processes belonging to Allergan and Medytox. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1954.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.


© Business Wire 2020
All news about EVOLUS, INC.
01/05EVOLUS, INC. : Termination of a Material Definitive Agreement, Results of Operat..
AQ
2020EVOLUS : Provides Update on United States International Trade Commission Case
AQ
2020US ITC Blocks Imports of Jeuveau Wrinkle Treatment -- Bloomberg
DJ
2020Evolus Provides Update on United States International Trade Commission (ITC) ..
GL
2020EVOLUS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
2020DEADLINE REMINDER : Law Offices of Howard G. Smith Reminds Investors of Looming ..
PR
2020EOLS INVESTOR ALERT : Bronstein, Gewirtz & Grossman, LLC Reminds Evolus, Inc. Sh..
BU
2020THE LAW OFFICES OF FRANK R. CRUZ : Reminds Investors of Looming Deadline in the ..
BU
2020DEADLINE ALERT : Bragar Eagel & Squire, P.C. Reminds Investors That a Class Acti..
BU
2020EVOLUS : ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Evolus, Inc. Investors of Impor..
BU
More news
Financials (USD)
Sales 2020 58,3 M - -
Net income 2020 -65,4 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,41x
Yield 2020 -
Capitalization 223 M 223 M -
Capi. / Sales 2020 3,83x
Capi. / Sales 2021 2,51x
Nbr of Employees 125
Free-Float 66,0%
Chart EVOLUS, INC.
Duration : Period :
Evolus, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOLUS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 7,13 $
Last Close Price 6,62 $
Spread / Highest target 66,2%
Spread / Average Target 7,63%
Spread / Lowest Target -39,6%
EPS Revisions
Managers and Directors
NameTitle
David Moatazedi President, Chief Executive Officer & Director
Vikram Malik Chairman
Alejandro Sabad Vice President-Operations
Lauren P. Silvernail Chief Financial & Accounting Officer
Rui Avelar Chief Medical Officer, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
EVOLUS, INC.97.02%223
GILEAD SCIENCES, INC.14.90%83 961
VERTEX PHARMACEUTICALS0.53%62 055
WUXI APPTEC CO., LTD.30.64%60 054
REGENERON PHARMACEUTICALS11.32%56 517
BEIGENE, LTD.44.94%32 552